AstraZeneca’s blood cancer drug meets main goal in late-stage trial

66

AstraZeneca Plc said on Thursday its blood cancer drug met the main goal of a final stage trial, taking the treatment one step closer to a marketing approval as the drugmaker seeks to bolster its oncology portfolio.

http://feeds.reuters.com/~r/reuters/healthNews/~3/pOWbK0PrlR8/astrazenecas-blood-cancer-drug-meets-main-goal-in-late-stage-trial-idUSKCN1T710V